

8EHQ-0204-155155

RECEIVED
OPPT CBIC

1803 BUILDING
January 28, 2004

04 FEB -6 AM 6:14

NR# 272799

CERTIFIED MAIL--RETURN RECEIPT REQUESTED
7000 0600 0025 5632 2004

COMPANY SANITIZED

2004 FEB 11 PM 12:06

RECEIVED
OPPT NCIC

Document Processing Center (7407M)
(Attn: TSCA Section 8(e) Coordinator)
Office of Pollution Prevention and Toxics
Environmental Protection Agency
1200 Pennsylvania Avenue, NW
Washington, DC 20460-0001

Re: Oxirane, 2,2'-[1,4-phenylenebis(oxymethylene)]bis-
CASRN 2425-01-6

Dear Sir/Madam:

The following information is being submitted by
pursuant to current guidance issued by
EPA indicating EPA's interpretation of Section 8(e) of the
Toxic Substances Control Act. has made no determination
as to whether a significant risk of injury to health or the
environment is actually presented by the findings.

The test substance was administered in the diet for 28 days to
Fischer 344 rats at targeted doses of 0, 10, 100, 200 or 1000
mg/kg/body weight/day. The 1000 mg/kg dosing was discontinued
after 5 days due to decreases in body weight by both males and
females.

Histopathologic changes in the stomach of males and females
given 200 mg/kg/day consisted of moderate diffuse epithelial
hyperplasia, hyperkeratosis, ulceration and slight to moderate
chronic inflammation of the nonglandular mucosa.

In the duodenum, very slight to slight diffuse epithelial
hyperplasia of the mucosa in males at the 100 and 200
mg/kg/day dose groups and females at the 200 mg/kg/day dose
were noted. Other changes in the duodenum consisted of very
slight multifocal dilatation and individual cell necrosis of
the crypts in both sexes at \geq 100 mg/kg/day. It is presumed



Document Processing Center (7407M)
January 28, 2004
Page 2

these effects were the direct result of irritancy of the test material to the mucosa.

No written report of these results is yet available.

Questions may be addressed to the undersigned.

Sincerely,

jt